Ian Mills's picture

Ian Mills

  • E-mailian.mills@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2022). The relationship between lipoprotein A and other lipids with prostate cancer risk: A multivariable Mendelian randomisation study. PLoS Medicine.
  • Show author(s) (2022). Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer. European Urology Open Science. 68-75.
  • Show author(s) (2022). Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer. Nature Communications. 12 pages.
  • Show author(s) (2022). A non-coding RNA balancing act: miR-346-induced DNA damage is limited by the long non-coding RNA NORAD in prostate cancer. Molecular Cancer. 22 pages.
  • Show author(s) (2021). Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nature Communications.
  • Show author(s) (2021). Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. Nature Communications.
  • Show author(s) (2021). Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24. Prostate Cancer and Prostatic Diseases.
  • Show author(s) (2021). Modulating the unfolded protein response with ONC201 to impact on radiation response in prostate cancer cells. Scientific Reports.
  • Show author(s) (2021). CaMKK2 facilitates Golgi-associated vesicle trafficking to sustain cancer cell proliferation. Cell Death & Disease. 1-12.
  • Show author(s) (2020). Sjögren syndrome/scleroderma autoantigen 1 is a direct Tankyrase binding partner in cancer cells. Communications Biology. 11 pages.
  • Show author(s) (2020). Methodology for the at-home collection of urine samples for prostate cancer detection. BioTechniques. 65-73.
  • Show author(s) (2020). Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9. Molecular Cancer Research. 1512-1521.
  • Show author(s) (2020). Inhibition of O-GlcNAc transferase activates tumor-suppressor gene expression in tamoxifen-resistant breast cancer cells. Scientific Reports. 1-10.
  • Show author(s) (2020). Identification and Validation of Leucine-rich alpha-2-glycoprotein 1 as a Noninvasive Biomarker for Improved Precision in Prostate Cancer Risk Stratification. European Urology Open Science. 51-61.
  • Show author(s) (2020). African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. International Journal of Cancer.
  • Show author(s) (2019). The β2-adrenergic receptor is a molecular switch for neuroendocrine transdifferentiation of prostate cancer cells. Molecular Cancer Research. 2154-2168.
  • Show author(s) (2019). Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer. Scientific Reports. 1-10.
  • Show author(s) (2019). IRE1α-XBP1s pathway promotes prostate cancer by activating c-MYC signaling. Nature Communications. 1-12.
  • Show author(s) (2019). High OGT activity is essential for MYC-driven proliferation of prostate cancer cells. Theranostics. 2183-2197.
  • Show author(s) (2019). Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. Scientific Reports. 1-11.
  • Show author(s) (2019). CDK9 Inhibition Induces a Metabolic Switch that Renders Prostate Cancer Cells Dependent on Fatty Acid Oxidation. Neoplasia. 713-720.
  • Show author(s) (2019). A four‐group urine risk classifier for predicting outcomes in patients with prostate cancer. BJU International. 609-620.
  • Show author(s) (2018). Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy. Annals of Oncology. 215-222.
  • Show author(s) (2018). Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. The BMJ. 1-7.
  • Show author(s) (2018). Identification of shared genetic variants between schizophrenia and lung cancer. Scientific Reports. 1-8.
  • Show author(s) (2018). Genetic factors influencing prostate cancer risk in Norwegian men. The Prostate. 186-192.
  • Show author(s) (2017). c-Myc antagonises the transcriptional activity of the androgen receptor in prostate cancer affecting key gene networks. EBioMedicine. 83-93.
  • Show author(s) (2017). The cancer-associated cell migration protein TSPAN1 is under control of androgens and its upregulation increases prostate cancer cell migration. Scientific Reports.
  • Show author(s) (2017). Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nature Communications.
  • Show author(s) (2017). Molecular subgroup of primary prostate cancer presenting with metastatic biology. European Urology. 509-518.
  • Show author(s) (2017). Lipid degradation promotes prostate cancer cell survival. OncoTarget. 38264-38275.
  • Show author(s) (2017). Dual transcriptome of the immediate neutrophil and Candida albicans interplay. BMC Genomics. 696.
  • Show author(s) (2017). Correction to: Dual transcriptome of the immediate neutrophil and Candida albicans interplay. BMC Genomics. 863.
  • Show author(s) (2017). Bromodomain-containing proteins in prostate cancer. Molecular and Cellular Endocrinology. 31-40.
  • Show author(s) (2017). Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics. 1-11.
  • Show author(s) (2017). Androgen receptor deregulation drives bromodomain-mediated chromatin alterations in prostate cancer. Cell reports. 2045-2059.
  • Show author(s) (2016). Using the fluorescent properties of STO-609 as a tool to assist structure-function analyses of recombinant CaMKK2. Biochemical and Biophysical Research Communications - BBRC. 102-107.
  • Show author(s) (2016). The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer. European Urology. 214-218.
  • Show author(s) (2016). Somatic Genomics and Clinical Features of Lung Adenocarcinoma: A Retrospective Study. PLoS Medicine.
  • Show author(s) (2016). Mapping Protein-DNA Interactions Using ChIP-exo and Illumina-Based Sequencing. Methods in molecular biology. 119-137.
  • Show author(s) (2016). Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism. OncoTarget. 12464-12476.
  • Show author(s) (2016). HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer. OncoTarget. 74734-74746.
  • Show author(s) (2016). Glycosylation is an androgen-regulated process essential for prostate cancer cell viability. EBioMedicine. 103-116.
  • Show author(s) (2016). Gene regulatory mechanisms underpinning prostate cancer susceptibility. Nature Genetics. 387-397.
  • Show author(s) (2016). Data for the co-expression and purification of human recombinant CaMKK2 in complex with calmodulin in Escherichia coli. Data in Brief. 733-740.
  • Show author(s) (2016). Choline Kinase Alpha as an Androgen Receptor Chaperone and Prostate Cancer Therapeutic Target. Journal of the National Cancer Institute.
  • Show author(s) (2016). Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells. Epigenetics & Chromatin.
  • Show author(s) (2016). Cell cycle-coupled expansion of AR activity promotes cancer progression. Oncogene. 1655-1668.
  • Show author(s) (2015). UAP1 is overexpressed in prostate cancer and is protective against inhibitors of N-linked glycosylation. Oncogene. 3744-3750.
  • Show author(s) (2015). The androgen receptor controls expression of the cancerassociated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. OncoTarget. 34358-34374.
  • Show author(s) (2015). Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLOS ONE.
  • Show author(s) (2015). Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer. Molecular Cancer Research. 620-635.
  • Show author(s) (2015). Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer. OncoTarget. 12587-12602.
  • Show author(s) (2015). Macroautophagic cargo sequestration assays. Methods. 25-36.
  • Show author(s) (2015). Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study. EBioMedicine. 1133-1144.
  • Show author(s) (2015). Glucocorticoid receptor and Klf4 co-regulate anti-inflammatory genes in keratinocytes. Molecular and Cellular Endocrinology. 281-289.
  • Show author(s) (2015). Genetic sharing with cardiovascular disease risk factors and diabetes reveals novel bone mineral density loci. PLOS ONE.
  • Show author(s) (2015). Divergent androgen regulation of unfolded protein response pathways drives prostate cancer. EMBO Molecular Medicine. 788-801.
  • Show author(s) (2015). Autophagic bulk sequestration of cytosolic cargo is independent of LC3, but requires GABARAPs. Experimental Cell Research. 21-38.
  • Show author(s) (2015). Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLOS ONE.
  • Show author(s) (2015). A differential protein solubility approach for the depletion of highly abundant proteins in plasma using ammonium sulfate. The Analyst. 8109-8117.
  • Show author(s) (2014). The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches. PLOS ONE. 32 pages.
  • Show author(s) (2014). The ETS family member GABPα modulates androgen receptor signalling and mediates an aggressive phenotype in prostate cancer. Nucleic Acids Research (NAR). 6256-6269.
  • Show author(s) (2014). Studying N-linked glycosylation of receptor tyrosine kinases. Methods in molecular biology. 103-109.
  • Show author(s) (2014). Shared common variants in prostate cancer and blood lipids. International Journal of Epidemiology. 1205-1214.
  • Show author(s) (2014). Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO Journal. 1365-1382.
  • Show author(s) (2014). Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Medical Genomics. 513.
  • Show author(s) (2014). HES6 drives a critical AR transcriptional programme to induce castration‐resistant prostate cancer through activation of an E2F1‐mediated cell cycle network. EMBO Molecular Medicine. 651-661.
  • Show author(s) (2014). Endosomal signalling and oncogenesis. Methods in Enzymology. 179-200.
  • Show author(s) (2014). Androgen-regulated metabolism and biosynthesis in prostate cancer. Endocrine-Related Cancer. T57-T66.
  • Show author(s) (2013). The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer. European Urology. 702-708.
  • Show author(s) (2013). The Androgen Receptor Induces a Distinct Transcriptional Program in Castration-Resistant Prostate Cancer in Man. Cancer Cell. 35-47.
  • Show author(s) (2013). O-GlcNAc Transferase Integrates Metabolic Pathways to Regulate the Stability of c-MYC in Human Prostate Cancer Cells. Cancer Research.
  • Show author(s) (2013). N-Linked Glycosylation Supports Cross-Talk between Receptor Tyrosine Kinases and Androgen Receptor. PLOS ONE. 10 pages.
  • Show author(s) (2013). Modulation of intracellular calcium homeostasis blocks autophagosome formation. Autophagy. 1475-1490.
  • Show author(s) (2013). Exome Sequencing of Prostate Cancer Supports the Hypothesis of Independent Tumour Origins. European Urology. 347-353.
  • Show author(s) (2013). Disseminated tumor cells and their prognostic significance in non-metastatic prostate cancer patients. International Journal of Cancer. 149-155.
  • Show author(s) (2012). PIAS1 Is Increased in Human Prostate Cancer and Enhances Proliferation through Inhibition of p21. American Journal of Pathology. 2097-2107.
  • Show author(s) (2012). Molecular Subtyping of Primary Prostate Cancer Reveals Specific and Shared Target Genes of Different ETS Rearrangements. Neoplasia. 600-+.
  • Show author(s) (2012). Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proceedings of the National Academy of Sciences of the United States of America. 11252-11257.
  • Show author(s) (2012). ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. Journal of Clinical Investigation. 4621-4634.
  • Show author(s) (2011). The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis. EMBO Journal. 2719-2733.
  • Show author(s) (2011). Principles for the post-GWAS functional characterization of cancer risk loci. Nature Genetics. 513-518.
  • Show author(s) (2011). Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO Journal. 3019-3027.
  • Show author(s) (2010). Taking Risks with Translational Research. Science Translational Medicine. 4 pages.
Academic lecture
  • Show author(s) (2013). Molecular and Structural Characterization of Sjögren syndrome/scleroderma autoantigen 1, a new binding partner of Tankyrase regulated by the oncogene c-Myc.
  • Show author(s) (2016). Maintaining a Healthy Balance: Targeting TERT to Stem Benign Prostatic Hyperplasia. European Urology. 555-556.
  • Show author(s) (2015). Molecular subtyping of prostate cancer: a partnership model. European Urology. 568-569.
  • Show author(s) (2011). Bridging the gaps: From risk loci via non-coding RNAs to gene networks and prostate cancer phenotypes. Cell Cycle. 4204-4204.
Short communication
  • Show author(s) (2016). Pleiotropic analysis of lung cancer and blood triglycerides. Journal of the National Cancer Institute. 1-4.
  • Show author(s) (2012). Androgen Receptor Affects Glycosylation Pathways to Alter Growth Factor Receptor Signalling. European Journal of Cancer. S72-S73.
  • Show author(s) (2017). O-GlcNAc transferase inhibition in breast cancer cells .
  • Show author(s) (2016). Inhibition of O-GlcNAc transferase in breast cancer cells .
  • Show author(s) (2016). Inhibition of O-GlcNAc transferase in breast cancer cells.
  • Show author(s) (2014). Metabolic and transcriptomic profiling of cancer cells treated with O-linked N-acetylglucosamine transferase inhibitor (STO45849).
  • Show author(s) (2022). Author Correction: Hyperpolarised <sup>13</sup>C-MRI identifies the emergence of a glycolytic cell population within intermediate-risk human prostate cancer (Nature Communications, (2022), 13, 1, (466), 10.1038/s41467-022-28069-2). Nature Communications.
  • Show author(s) (2020). Correction to: Human-Based Exposure Levels of Perfluoroalkyl Acids May Induce Harmful Effects to Health by Disrupting Major Components of Androgen Receptor Signalling In Vitro (Exposure and Health, (2020), 12, 3, (527-538), 10.1007/s12403-019-00318-8). Exposure and Health. 929.
  • Show author(s) (2017). Erratum: Dual transcriptome of the immediate neutrophil and Candida albicans interplay. [BMC Genomics. 18, (2017) (696)] DOI: 10.1186/s12864-017-4097-4. BMC Genomics. 1-21.
  • Show author(s) (2017). Corrigendum to "Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study" [EBioMedicine 2 (9) (2015) 1133-1144] (S2352396415300712) (10.1016/j.ebiom.2015.07.017)). EBioMedicine. 238-238.
  • Show author(s) (2015). Correction: Abundant genetic overlap between blood lipids and immune-mediated diseases indicates shared molecular genetic mechanisms. PLOS ONE.
Academic literature review
  • Show author(s) (2021). Vascular normalisation as the stepping stone into tumour microenvironment transformation. British Journal of Cancer. 324-336.
  • Show author(s) (2021). The Interplay Between Prostate Cancer Genomics, Metabolism, and the Epigenome: Perspectives and Future Prospects. Frontiers in Oncology.
  • Show author(s) (2017). The importance of DNA methylation in prostate cancer development. Journal of Steroid Biochemistry and Molecular Biology. 1-15.
  • Show author(s) (2016). The role of glycans in the development and progression of prostate cancer. Nature reviews. Urology. 324-333.
  • Show author(s) (2016). CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions. Nucleic Acids Research (NAR). 10588-10602.
  • Show author(s) (2014). Maintaining and reprogramming genomic androgen receptor activity in prostate cancer. Nature Reviews Cancer. 187-198.
  • Show author(s) (2014). HOXB13, RFX6 and prostate cancer risk. Nature Genetics. 94-95.
  • Show author(s) (2012). Nuclear translocation and functions of growth factor receptors. Seminars in Cell and Developmental Biology. 165-171.
  • Show author(s) (2012). Chromatin binding by the androgen receptor in prostate cancer. Molecular and Cellular Endocrinology. 44-51.

More information in national current research information system (CRIStin)